SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve who wrote (320)6/4/1999 12:43:00 AM
From: Steve  Read Replies (2) of 496
 
Piper Jaffrey issued a scathing downgrade of Guilford on May 5. Although the buy rating was maintain, they lowered the target price to $13. The read between the lines of the report was these guys seemed to be fuming about the continual disappointments out of Guilford. Although the report acknowledged the anticipated introduction of three compounds into the clinic this year, it didn't seem to think that there is much to drive the stock just short of sustained earnings.

This probably explains why BVF bailed out of Guilford. I hope they are wrong. How much longer can this be dead money?

If Guilford isn't going to put itself up for sale, then, based on the information in the Piper report, they should sell the drug delivery division and Dopascan (both legacies from Scios). Scios was right in seeing little value in these two items and dumping into Guilford. Guilford should then focus its research in neuroscience. Its called strategic redeployment of assets. If management doesn't see this, then they should be fired.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News